Skip to main content
Premium Trial:

Request an Annual Quote

VASTox, Alnylam, Hayashi Kasei

Premium
VASTox Changes Name to Summit Corporation
 
Summit Corporation this week announced the completion of the company’s name change from VASTox. The change in name was approved by shareholders at the company’s annual shareholder’s meeting on July 19.
 

 
Alnylam Licenses siRNA Patents to Japanese Distributor Hayashi Kasei
 
Alnylam said this week that it has granted a non-exclusive license for its Kreutzer-Limmer siRNA patents to Hayashi Kasei, an siRNA supplier in Japan and Korea.
 
Under the agreement, the Osaka, Japan-based Hayashi Kasei will be able to use the siRNAi patents to provide RNAi research products and services, Alnylam said.
 
"With approximately 30 licenses granted in the US, European, and Asian markets, including 14 with research product suppliers, we believe that the vast majority of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property," Alnylam COO Barry Greene said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.